GT 2b; since 80’s, no prior tx, sofosbuvir and daclatasvir compounded from API’s at Kingswood Pharmacy in Sydney, started tx nov 6,2015, undetected at 4 wks, UND at 8 weeks, UND at 1 week after EOT, UND at 4 weeks after EOT and UND at 8 weeks after EOT. I feel GOOD!! I knew that I WOULD!””
At face value it looks as if Bristol-Myer are trying to take a more reasonable, broad and humane approach to the treatment of Hep C. I imagine there must be some hurdles to jump to do any collaborating with Gillead. Good to see the increasing media focus on Hep C and the broader distribution.
This will allow manufacture of a combination Sofosbuvir/Daclatasvir single pill similar to Harvoni or Twinvir (Sofobuvir/Ledipasvir) which hasn’t been available till now. So single pill treatments available to cover all genotypes soon now I believe.
Only for developing countries but will simplify treatment in those areas and presumably cheaper as Dac is much less expensive than Led.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Treatment naive
F 3/4
Genotype 1 a & b
V/L 17 MILLION
Started Harvoni 11th Dec 2015 for 12 weeks
4 weeks VL UND
6 WEEKS ALT 32, AST 34
EOT 03/03 2016 ! UND
ALT 34, AST 26
04.04.2016 SVR 4
26.05.2016 SVR 12
16.08.2016 SVR 24